A phase 1/2 study of metronomic 5-fluorouracil (5-FU) plus nabpaclitaxel, bevacizumab, leucovorin, and oxaliplatin (FABLOx) in patients with metastatic pancreatic cancer

被引：0

作者：

Vincent, Picozzi ^{[1
]}

Vaibhav, Sahai ^{[2
]}

Diane, Simeone ^{[2
]}

Caio, Rocha Lima ^{[3
]}

Allyson, Ocean ^{[4
]}

Philip, Philip ^{[5
]}

Wasif, Saif ^{[6
]}

Aparna, Kalyan ^{[7
]}

Michael, Ondovik ^{[8
]}

Jack, Shiansong Li ^{[8
]}

Chrystal, Louis ^{[8
]}

机构：

[1] Virginia Mason, Seattle, WA USA

[2] Univ Michigan, Ann Arbor, MI 48109 USA

[3] Gibbs Canc Ctr, Res Inst, Spartanburg, SC USA

[4] Weill Cornell Med Coll, New York, NY USA

[5] Karmanos Canc Ctr, Detroit, MI USA

[6] Tufts Med Ctr, Boston, MA USA

[7] Northwestern Univ, Feinberg Sch Med, Chicago, IL 60611 USA

[8] Celgene Corp, Summit, NJ USA

来源：

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

P-231

引用

页数：2